ライフサイエンスコーパス: first-in-class

1 logy drugs were more likely to be orphan and first in class.

2 Ezetimibe is the first in class 2-azetidinone that decreases plasma chole

3 b (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for tr

4 ere we show the properties of analogues of a first-in-class 4R-tau lead, [(18)F]OXD-2115, using ligan

5 Herein, we report the development of 2 first-in-class (89)Zr-labeled PET tracers that enable th

6 The small molecules described here represent first-in-class activators of PKM2.

7 e and postoperative infusion of acadesine, a first-in-class adenosine-regulating agent, was associate

8 Pitolisant is a first-in-class agent utilizing histamine to improve wake

9 This first-in-class agent, with its novel mechanism of action

10 r-binding OR, and in addition, demonstrate a first-in-class agonist to further research in insect OR

11 Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates th

12 cacy of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of

13 ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy

14 Belzutifan, a first-in-class allosteric HIF2 inhibitor, has advanced t

15 Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase

16 assess efficacy and safety of firibastat, a first-in-class aminopeptidase A inhibitor preventing con

17 mpound 1 is a candidate for development as a first-in-class analgesic.

18 Brentuximab vedotin, first in class and gold standard, was chosen for a proof

19 these studies highlighted compound 31 as the first-in-class and a suitable candidate for in vivo prec

20 new oncology drug approvals were more often first-in-class and diffused more widely across important

21 ssessed the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor

22 Orencia is the first-in-class antagonist of CD28 costimulation.

23 Vamorolone is a first-in-class anti-inflammatory investigational drug th

24 pendent cell cytotoxicity using lacutamab, a first-in-class anti-KIR3DL2 humanized antibody, selectiv

25 been reported.Sacituzumab govitecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (

26 ent of Cubicin (daptomycin-for-injection), a first-in-class antibiotic approved for treatment of skin

27 the further drug development of Ramizol as a first-in-class antibiotic for the treatment of CDI.

28 Designed sustainably to deliver novel and first-in-class antibiotics targeting key human health ga

29 Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against

30 CMG901 is a novel first-in-class antibody-drug conjugate with a humanised

31 rthermore, DT2216 may be developed as a safe first-in-class anticancer agent targeting BCL-X(L).

32 AS1411 is a first-in-class anticancer agent, currently in phase II c

33 ated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative, plus cyt

34 Retigabine (RTG) is a first-in-class antiepileptic drug that suppresses neuron

35 Gal-B2 may lead to development of first-in-class antiepileptic drugs.

36 Fosmanogepix, a first-in-class antifungal agent, has potent activity aga

37 Exebacase is a first-in-class antistaphylococcal lysin that is rapidly

38 Exebacase, a first-in-class antistaphylococcal lysin, is a direct lyt

39 ONC201/TIC10 is a first-in-class antitumor agent that induces TRAIL pathwa

40 and preclinical characterization of CD388, a first-in-class antiviral drug-Fc conjugate (DFC), in mic

41 Pimodivir is a first-in-class antiviral for influenza A under developme

42 phase III trial suggest that plitidepsin, a first-in-class antiviral, may have a positive benefit-ri

43 ds was affected by the drug fulvestrant, the first-in-class approved selective estrogen receptor degr

44 Fostemsavir, a prodrug of the first-in-class attachment inhibitor, temsavir, is indica

45 Gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antib

46 GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacteriu

47 leveraged for the therapeutic development of first-in-class BET inhibitors and other targeted strateg

48 We previously discovered first-in-class beta-arrestin-biased agonists of dopamine

49 First-in-class biased UmBLs (BUmBLs) targeting the human

50 Delamanid, a-first-in-class bicyclic nitroimidazole, was recently app

51 Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of t

52 s further increases bone mass, we engineer a first-in-class bispecific antibody with single residue p

53 he metabolic liabilities of PQR620 (52), the first-in-class brain penetrant TORKi showing efficacy in

54 are now being realized with the approval of first-in-class BRCA-targeted therapies for ovarian cance

55 A first-in-class cannabinoid analog called lenabasum that

56 ess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic

57 This first-in-class caspase inhibitor is now the subject of t

58 on of STM2457, a highly potent and selective first-in-class catalytic inhibitor of METTL3, and a crys

59 Here, we report the development of first-in-class cell-penetrating lipopeptide "pepducin" a

60 These studies provide a first-in-class chemical probe to study SCA10 RNA toxicit

61 OATD-01 is the first-in-class CHIT1 inhibitor, currently completed phas

62 ultimately resulted in the discovery of the first-in-class clinical candidate BAY 2413555 (27).

63 y leading ultimately to the highly selective first-in-class clinical candidate roblitinib.

64 d a new understanding of immunity, enabled a first-in-class clinical trial using bioelectronic device

65 mia (CML) cell lines with commercial and the first-in-class clinical WEE1 kinase inhibitor MK1775 con

66 DNL201 is an investigational, first-in-class, CNS-penetrant, selective, ATP-competitiv

67 Belatacept is a first-in-class co-stimulation blocker in development for

68 The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of

69 Eculizumab, the first-in-class complement inhibitor, was approved for PN

70 Collectively, first-in-class compound 11c shows promise as a therapeut

71 d plasma, and more potent, compared with the first-in-class compound ferrostatin-1 (Fer-1).

72 Therefore, CD-160130 is a promising first-in-class compound to attempt oncologic therapy wit

73 Elesclomol, an investigational first-in-class compound, induces oxidative stress, trigg

74 ng new drugs to inhibit viruses resistant to first-in-class compounds.

75 oline tetrathiomolybdate (WTX101) is an oral first-in-class copper-protein-binding molecule that targ

76 roved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly

77 These first-in-class covalent K-Ras inhibitors demonstrate tha

78 favorable pharmacokinetic properties and the first-in-class covalent PL(pro) inhibitors.

79 Borussertib, a first-in-class covalent-allosteric AKT inhibitor, displa

80 roader application of KPT-330 (selinexor), a first-in-class CRM1 inhibitor recently approved for rela

81 anced to clinical development as a potential first-in-class D1 PAM and is now in phase 2 studies for

82 MP0250 is a first-in-class DARPin drug candidate with suitable toler

83 ged PROTAC strategy, we discovered MS28, the first-in-class degrader of cyclin D1, which lacks a smal

84 Here, we report a first-in-class degrader of MEK1/2, MS432 (23), which pot

85 better selectivity index and represents the first-in-class DENV-NS5 allosteric inhibitor able to tar

86 areas, modalities, route of administration, first-in-class designation, approval times, and expedite

87 ith the desired functionality, including the first-in-class devices including sensors and memristors,

88 Ervogastat is a first-in-class DGAT2 inhibitor that addressed potential

89 t and orthogonal counterscreens identified a first-in-class direct-acting RABV inhibitor, GRP-60367,

90 lpituzumab teserine (Rova-T; SC16LD6.5) is a first-in-class DLL3-targeted antibody-drug conjugate wit

91 iomarkers for treatment with AsiDNA, a novel first-in-class DNA repair inhibitor.

92 MT1 with an aptamer platform, we generated a first-in-class DNMT1-targeted approach - aptaDiR.

93 The first in-class drug, avibactam, as well as several other

94 tured bacteria, is considered as a promising first-in-class drug candidate for clinical development.

95 dentification of DNDI-VL-2098 as a potential first-in-class drug candidate for visceral leishmaniasis

96 We identified the first-in-class drug candidates that transiently sequeste

97 Recent reports of new chemical entities and first-in-class drug candidates, and confirmation of indi

98 Tocilizumab is the first-in-class drug developed to treat diseases mediated

99 Bempedoic acid (BPA) is a first-in-class drug for the treatment of hypercholestero

100 d and Drug Administration-approved Picato, a first-in-class drug for the treatment of the precancerou

101 f HIV-infected patients with nevirapine, the first-in-class drug still widely used, especially in dev

102 d in EAE and that laquinimod may represent a first-in-class drug targeting AhR for the treatment of m

103 Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation

104 edict ligands from virtual libraries yielded first-in-class, drug-like ligands for 7 of the 16 WDR do

105 he basis for the development of IDO1 PAMs as first-in-class drugs in autoimmune/neuroinflammatory dis

106 rugs, products in certain therapeutic areas, first-in-class drugs, therapeutic agents that received a

107 market, such as accelerating approval of non-first-in-class drugs, will likely not result in lower dr

108 cancer treatment through the development of "first-in-class" drugs that target oncogenic coactivators

109 We also report the discovery of first-in-class dual bromodomain-kinase inhibitors outsid

110 and-directed degrader targeting the AR via a first-in-class dual mechanism of AR degradation and anta

111 in the 2014 FDA approval of suvorexant as a first-in-class dual orexin receptor antagonist for the t

112 Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Pro

113 ting EGFR degrader, MS39 (compound 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrad

114 e emergence of new technologies coupled with first-in-class entries in ophthalmology are highly antic

115 MLN4924 is a first-in-class experimental cancer drug that inhibits th

116 study population, which ultimately supported first-in-class FDA clearance for extragenital assays.

117 First-in-class (FIC) drugs and drugs with Orphan Drug De

118 like (MASTL) represents a novel target and a first-in-class (FIC) opportunity to provide a new impact

119 motif, which results in pharmacology that is first-in-class for the central melanocortin receptors.

120 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody ta

121 C3 is a first-in-class functionalized water-soluble fullerene th

122 This effort represents the discovery of first-in-class GAB1 PH domain inhibitors with potential

123 The compounds reported herein represent a first-in-class genotype-selective series that specifical

124 essful third-generation approach leverages a first in class glycosylation of a phosphoglycerol-functi

125 flunarizine and related compounds represent first-in-class HCV fusion inhibitors that merit consider

126 R is now being advanced to human trials as a first-in-class HD PET radiotracer.

127 Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved f

128 The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication

129 PT2385 is a first-in-class HIF-2alpha antagonist.

130 Belzutifan, a first-in-class HIF-2alpha inhibitor, has shown antitumou

131 port the discovery and characterization of a first-in-class, highly selective allosteric inhibitor of

132 ns and identified a chemically well-behaved, first-in-class hit with nanomolar anti-RABV potency that

133 he C-3' dimethyl group of bevirimat (2), the first-in-class HIV maturation inhibitor, which is curren

134 The first-in-class HIV-1 maturation inhibitor bevirimat was

135 A first-in-class HK2 antisense oligonucleotide suppresses

136 Belzutifan is a first-in-class hypoxia-inducible factor subunit 2alpha (

137 ty and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours ex

138 Ipilimumab is the first-in-class immunotherapeutic for blockade of CTLA-4

139 a highly attractive target for developing a first-in-class immunotherapy, albeit one with a potentia

140 of this analysis, we have investigated which first in class inhibitor that entered phase I clinical t

141 4-phenyl-1H-imidazol-5-yl)phenol (H23), as a first-in-class inhibitor for yeast GS 2 (yGsy2p).

142 Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK)

143 Pimodivir, a first-in-class inhibitor of influenza virus polymerase b

144 However, MNKI-85, a first-in-class inhibitor of Mnk2, can be used as a power

145 identified as a potent, orally bioavailable first-in-class inhibitor of orthopoxvirus egress from in

146 Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA polymerase I transcripti

147 evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein X

148 AZD1775 is a first-in-class inhibitor of Wee1 kinase with single-agen

149 It is a first-in-class inhibitor targeting the endonuclease acti

150 the small molecule SBI-0640756 (SBI-756), a first-in-class inhibitor that targets eIF4G1 and disrupt

151 CDK7/12/13 inhibition using the first-in-class inhibitor THZ1 or RNAi blocks stress-indu

152 Ceapins are first-in-class inhibitors that can be used to explore bo

153 imes, and in vivo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibitio

154 raction Discovery and Exploration (SLIDE), a first-in-class interpretable machine learning technique

155 We report the development of a first-in-class intracellular PAR1 inhibitor with optimiz

156 Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibito

157 As a first-in-class investigational oral antibiotic with acti

158 Netarsudil QD (PM), a first-in-class IOP-lowering medication, was noninferior

159 identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune

160 Herein we report the discovery of a first-in-class KHK inhibitor, PF-06835919 (8), currently

161 Analysis of the target validation history of first in class kinase inhibitors revealed a long delay b

162 Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidel

163 Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that

164 eukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor.

165 This first-in-class macrocyclic peptide modulator of the hedg

166 The first-in-class maturation inhibitor bevirimat (BVM) fail

167 Bevirimat (BVM), the first-in-class maturation inhibitor drug, targets the 6H

168 This compound represents a first-in-class MC3R selective agonist.

169 and humans, making NOX4 a prime target for a first-in-class mechanism-based, cytoprotective therapy i

170 Discovery of first-in-class medicines for treating cancer is limited

171 These studies warrant identification of first-in-class MEIS inhibitors as potential pharmaceutic

172 Here we introduce a first-in-class microRNA-sensitive oncolytic Zika virus (

173 , a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor that attenuates and eve

174 upport our discovery that roseltide rT1 is a first-in-class mitochondria-targeting, cysteine-rich pep

175 dent on ML-based TO assessment, we deliver a first-in-class ML-based target pharmacology assessment f

176 (64)Cu-RYM2 is a first-in-class MMP-targeted positron emission tomography

177 Consequently, TRIP emerges as a first-in-class modulator of the scaffold protein NUBP2,

178 IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a

179 Eculizumab, a first-in-class monoclonal antibody that inhibits termina

180 We used a first-in-class, monoclonal antibody (MABp1) cloned from

181 Ibalizumab (formerly TNX-355) is a first-in-class, monoclonal antibody inhibitor of CD4-med

182 On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I eval

183 E-101 solution is a first-in-class myeloperoxidase-mediated antimicrobial de

184 Daily treatment of rats with the first-in-class NAMPT stimulator, P7C3-A20, prevented beh

185 A first-in-class neutralizing antibody targeting SCUBE3, w

186 we report the discovery and development of a first-in-class non-covalent small-molecule inhibitor of

187 Tanaproget represents a potential first-in-class nonsteroidal PR agonist for contraception

188 ies support the further optimization of this first-in-class NOTCH1 inhibitor with dual selectivity: l

189 rt the development and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(

190 Efgartigimod, a first-in-class novel human IgG1 Fc fragment, binds the n

191 Compound 71 is a first-in-class nucleoside RSV polymerase inhibitor that

192 eft ventricular dysfunction and could be the first in class of a new therapeutic agent.

193 ng excitatory neurotransmission, providing a first-in-class optogenetic tool for persistent, light-tr

194 On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3

195 Idelalisib is a first-in-class oral inhibitor of PI3Kdelta that has show

196 We aimed to investigate the efficacy of a first-in-class oral P2X3 antagonist, AF-219, to reduce c

197 Voxelotor (GBT440) is a first-in-class oral therapy specifically developed to tr

198 pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed

199 d the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patients with fo

200 AQX-1125 is a first-in-class, oral SHIP1 activator with a novel anti-i

201 Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2

202 Eltrombopag (SB-497 115) is a first-in-class, oral, small-molecule, nonpeptide agonist

203 its continued development as a LANCL2-based, first-in-class orally active therapeutic for IBD.

204 Compound 2 represents a first-in-class, orally bioavailable, novel compound that

205 characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PT

206 dioides species that is being developed as a first-in-class orphan product for treatment of coccidioi

207 reclinical studies, neladenoson bialanate, a first-in-class partial adenosine A1 receptor agonist, ha

208 BRD0639 is a first-in-class PBM-competitive inhibitor that can suppor

209 This study uses a first-in-class PDI inhibitor entering clinical developme

210 se or oncology, and more than 10 potentially first-in-class peptide therapeutics are in the pipeline.

211 Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets amino

212 MTI-101 is a first-in-class peptidomimetic that binds a CD44/ITGA4 co

213 re-based drug design effort that led to this first-in-class pharmacologic agent.

214 by recapitulating the phenotype using BT5, a first-in-class pharmacologic inhibitor against NSD1.

215 chemical biology labs interested in creating first-in-class pharmacological probes for challenging pr

216 Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc f

217 y of [(11)C]-(R)-3 ([(11)C]-(R)-IPMICF16), a first-in-class positron emission tomography (PET) TrkB/C

218 assisted design of derivatives, yielded four first-in-class potent Sirt4 inhibitors.

219 Here, we report the discovery of (R)-PFI-2-a first-in-class, potent (Ki (app) = 0.33 nM), selective,

220 Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1

221 es, we advanced compound 9 to compound 15, a first-in-class, potent, selective, and bioavailable inhi

222 First in class, priority review, fast track, orphan drug

223 argeting chimera technology, we discovered a first-in-class PRMT5 degrader 15 (MS4322).

224 DRP-104 represents a first-in-class prodrug with differential metabolism in t

225 In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently a

226 onse rates of AL amyloidosis patients to the first-in-class proteasome inhibitor (PI) bortezomib, we

227 se 1 trials of bortezomib 10 years ago, this first-in-class proteasome inhibitor (PI) has contributed

228 rch & Development, L.L.C., Raritan, NJ) is a first-in-class proteasome inhibitor developed specifical

229 Dps is the first-in-class protein cage nanoparticle that can be tar

230 Bortezomib is a first in class proteosomal inhibitor, that is Food and D

231 We examined the potential of a first-in-class radiofluorinated small-molecule inhibitor

232 red the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific

233 r therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for rel

234 eported for a kinase ribozyme, making this a first-in-class ribozyme.

235 Here we show that HDAC3 inhibition using a first in class selective inhibitor, RGFP966, resulted in

236 Lumateperone (ITI-007) is a first-in-class selective and simultaneous modulator of s

237 We previously reported that a first-in-class selective class IIa histone deacetylase (

238 First-in-class selective PET tracers for imaging VEGFR-1

239 Selinexor is a novel, first-in-class, selective inhibitor of nuclear export co

240 L as a versatile reactive group for creating first-in-class serine hydrolase inhibitors.

241 e the design, synthesis, and evaluation of a first-in-class set of 5- to 7-membered ether-linked and

242 iscovery and characterization of RGLS4326, a first-in-class, short oligonucleotide inhibitor of micro

243 y potent, selective, orally efficacious, and first-in-class SHP2 inhibitor currently in clinical tria

244 A-552 represents a first-in-class small molecule antagonist of IL-36 signal

245 Herein, we report on the discovery of first-in-class small molecule compounds that inhibit the

246 he discovery and characterization of 10 e, a first-in-class small molecule degrader of PDCD2.

247 lography revealed that a potent, reversible, first-in-class small molecule inhibitor of the oncogenic

248 The first-in-class small molecule inhibitor OTX015 (MK-8628)

249 Further, we developed a first-in-class small molecule inhibitor toward FIEL1 tha

250 y and a structure-based design, we developed first-in-class small molecule inhibitors of the ASH1L SE

251 represents, to the best of our knowledge, a first-in-class small molecule that exerts a probe-depend

252 We identify two first-in-class small molecules that inhibit the NF-kappa

253 Most FDA approved, first-in-class small molecules were identified from phen

254 e discovery and characterization of PZL-A, a first-in-class small-molecule activator of mtDNA synthes

255 This first-in-class small-molecule activator targeting SERCA2

256 immunohistochemistry to evaluate a series of first-in-class small-molecule activators of PP2A (SMAPs)

257 Our approach is the first to identify a first-in-class small-molecule antagonist of activin bind

258 Here we report the discovery of a first-in-class small-molecule inhibitor targeting PurF,

259 ither RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we

260 thy volunteer Phase 1 trials, making it the "first-in-class" small-molecule LOXL2 inhibitor to enter

261 We have identified a first-in-class, small molecule inhibitor of the eukaryot

262 CUDC-907 is an oral, first-in-class, small molecule that is designed to inhib

263 Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p

264 A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog

265 Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator.

266 We developed a first-in-class, small-molecule PRMT5 inhibitor that bloc

267 Here we present MitoTNT, the first-in-class software for Mitochondrial Temporal Netwo

268 The first-in-class soluble guanylate cyclase (sGC) stimulato

269 vemurafenib (RG7204; PLX4032; RO5185426), a first-in-class, specific small molecule inhibitor of BRA

270 oval times, clinical approval success rates, first-in-class status, and global market diffusion.

271 ned in the presence of either abiraterone, a first-in-class steroidal inhibitor recently approved by

272 we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-J

273 This first-in-class study evaluated the anti-cholestatic effe

274 This first-in-class study supports further investigation of F

275 Ramizol, a first-in-class styrylbenzene based antibiotic, is an inv

276 Overall, sulfated coumarins represent first-in-class, sub-maximal inhibitors of thrombin.

277 [(11)C]AZ12204657 is a first-in-class surrogate imaging biomarker for pancreati

278 he discovery and development of olpasiran, a first-in-class, synthetic, double-stranded, N-acetylgala

279 enerated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (

280 3-expressing cancer cells and is a potential first-in-class targeted alpha-therapy in advanced HCC.

281 Mavacamten is a first-in-class targeted inhibitor of cardiac myosin, whi

282 efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase delta

283 extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new the

284 for the clinical development of CAL-101 as a first-in-class targeted therapy for CLL and related B-ce

285 RER-HCM is a phase 3 trial in oHCM testing a first-in-class, targeted strategy of myosin inhibition t

286 ACI-19278 and ACI-19626 are promising first-in-class TDP-43 PET tracers with the potential to

287 ntified a small molecule compound, C35, as a first-in-class TET inhibitor that specifically blocks th

288 dy AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create

289 disease-driver genes and are progressing as first-in-class therapeutic agents.

290 HCC, a novel molecular target in SDH, and a first-in-class therapy to treat the disease.

291 To surmount these challenges, we created a first-in-class, tri-part split luciferase consisting of

292 Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent

293 Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhi

294 ture of RAP1/TRF2 complex, we have developed first-in-class triazole-stapled peptides that block the

295 tly granted tissue-agnostic approval for the first-in-class TRK inhibitor larotrectinib for patients

296 The first-in-class utrophin modulator ezutromid/SMT C1100 wa

297 len-2-yl)benzo[d]oxazole (ezutromid, 1) is a first-in-class utrophin modulator that has been evaluate

298 We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in viv

299 It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied comp

300 Previously, we reported a first-in-class von Hippel-Lindau (VHL)-recruiting mitoge